Aravive Investor Presentation Deck

Subject ID Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3rd+ Line of Therapy; Literature Demonstrates 85% of Patients on their 3rd Line of Therapy have Progressive Disease by their First CT Scan¹ 19-0001 15-0000 01-0000 0-0003 20-0004 00-000 08-0003. 12-000 12-0001 103-0003 08-0001 17-0003 08-0004 17-0000 PFS Months for Per-Protocol 10 mg/kg and 15 mg/kg AVB500+Pac Subjects 1 20 (10) 31 2.9 18 (10) 1.7 (10) 2 Dev (10) Dew (10) 1 30/0 (10) 10 (10) 4 60(15) 6 7 77 (10) 73 (1) 1 93(10) 13(10) (10) Confirmed Best Overall Response + >MEC 0 Progressive Dis Stable Disease Partial Response Complete Response 10 Study Months Response maintained after discontinuation of chemotherapy at Cycle 6 * = PPS duration censored at date of last radiologic assessment <-MEC 15 (15) * Start of Confirmed CR Start of Confirmed PR 13 15 Change from baseline ( 60% 40% 20% ON -20% -60% 2025 10 17-0002 06-0001 15% 02-0002 Largest Change in Target Lesion Burden for Per-Protocol 10 mg/kg and 15 mg/kg AVB-500+Pac Subjects 08-0003 BEN 19-0002 110 02-0004 0 A Ď 12:0001 Subject 4TAN 07-0000 Confirmed Best Overall Response Progressive Disease + MEC Stable Disease Partial Respons Complete conse 0 <-MEC BOOGD 440% 16-0002 2300 40 2000-40 000 01-0005 16

View entire presentation